BIOS Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
BIOS Health logo

BIOS Health

EmergingHealthcare

General

Neural interface company developing closed-loop bioelectronic medicine devices; decodes peripheral nerve signals to treat diabetes, hypertension, and inflammatory conditions.

AI VisibilityBeta
Overall Score
D38
Category Rank
#476 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
44
Gemini
40

About

BIOS Health is a neural interface and closed-loop neuromodulation company developing bioelectronic medicine devices for treating chronic conditions. Founded in 2017 as a spinout from Cambridge University, BIOS Health builds implantable devices and software platforms that decode peripheral nerve signals to restore physiological function in patients with conditions including diabetes, hypertension, and inflammatory diseases. The company's approach combines machine learning with neural signal processing to enable real-time, adaptive therapy.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#476
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
35
ChatGPT
92
44
Perplexity
93
40
Gemini
89
33
Claude
96
40
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.